FDA label
What is Camzyos used for?
Camzyos contains mavacamten. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Camzyos?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Camzyos, capsule, gelatin coated
Indications and Usage, quoted from the label by Myokardia, Inc. (NDA214998). Cross-references to other label sections are left out.
CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Source: DailyMed label, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9, effective September 30, 2026. NDC 73625-111, one of 4 listings for this product.
Questions
What is Camzyos used for?
The FDA label says: “CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.”
What drug class is Camzyos?
FDA lists mavacamten in the Cardiac Myosin Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.